Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : BxC-I17e
Therapeutic Area : Dermatology
Study Phase : Phase I
Recipient : Brexogen
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Brexogen, BMI Korea Form Exosome Therapy Tech Transfer Deal
Details : Under the icensing agreement, BMI Korea has secured the exclusive rights of BxC-I17e, an innovative exosome-based injectable therapeutics for the treatment of Atopic Dermatitis.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : $2.3 million
February 19, 2025
Lead Product(s) : BxC-I17e
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Recipient : Brexogen
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : BMI2004
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluate the Safety and Tolerability of a Single-dose Administration of BMI2004 Inj.
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
June 28, 2023
Lead Product(s) : BMI2004
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BMI2006
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Treatment of Moderate to Severe Glabellar Lines (BMI2006)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
September 08, 2022
Lead Product(s) : BMI2006
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable